Spots Global Cancer Trial Database for Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases
Official Title: Measuring Molecular Residual Disease in Colorectal Cancer After Primary Surgery and Resection of Metastases
Study ID: NCT03189576
Interventions
Study Description
Brief Summary: Circulating tumour DNA (ctDNA) is a promising tool when monitoring the residual disease in colorectal cancer (CRC). Current staging procedures are insufficient to identify the patient cohort at high risk, who might benefit from additional adjuvant therapy. We will show that the assessment of ctDNA is a non-invasive approach and easily taken at different time points via simple blood draw to monitor residual disease from the colorectal cancer patients after primary surgery. Minimal residual disease could be used in the future for individualized treatment decisions after primary surgery.
Detailed Description:
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
Tampere University Hospital, Tampere, , Finland
Contact Details
Name: Pirkko-Liisa Kellokumpu-Lehtinen, professor
Affiliation: Tampere University Hospital
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
